| SMN | second malignant neoplasm; stathmin |
|---|---|
| TR | recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu... |
| trach | trachea, tracheal, tracheostomy |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CBN | cannabinol; central benign neoplasm; Commission on Biological Nomenclature |
| neoplasm circulating cells | Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours. (12 Dec 1998) |
|---|---|
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
| neoplasm invasiveness | Ability of neoplasms to infiltrate and actively destroy surrounding tissue. (12 Dec 1998) |
| neoplasm metastasis | The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. The ability to metastasize is characteristic of all malignant neoplasms. (12 Dec 1998) |
| neoplasm recurrence, local | The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. (12 Dec 1998) |
| neoplasm regression, spontaneous | Disappearance of a neoplasm or neoplastic state without the intervention of therapy. (12 Dec 1998) |
| neoplasm, residual | Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication) (12 Dec 1998) |
| neoplasm seeding | The local implantation of tumour cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumour formation. (12 Dec 1998) |
| neoplasm staging | Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. (12 Dec 1998) |
| neoplasm transplantation | Experimental transplantation of neoplasms in laboratory animals for research purposes. (12 Dec 1998) |
| DNA, neoplasm | DNA present in neoplastic tissue. (12 Dec 1998) |
| drug resistance, neoplasm | Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (12 Dec 1998) |
| cancer, malignant melanoma | A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma. (12 Dec 1998) |
| canine malignant lymphoma | <tumour> A progressive fatal disease of dogs characterised by neoplastic transformation and proliferation of lymphoid cells, usually originating in solid lymphoid organs (lymphosarcoma) or bone marrow (lymphocytic leukaemia). (05 Mar 2000) |
| malignant | <oncology> Tending to become progressively worse and to result in death. Having the properties of anaplasia, invasion and metastasis, said of tumours. Origin: L. Malignans = acting maliciously (18 Nov 1997) |